Matrixx Initiatives Selects GolinHarris as Agency of Record for Z...(sidiary markets and sells Zicam® and...),Health

Date:1/8/2009

sidiary, markets and sells Zicam® and Nasal ComfortTM products in the cough and cold category. The company's flagship product, Zicam Cold Remedy nasal gel, is a patented, homeopathic remedy that has been clinically proven to reduce the duration and severity of the common cold. In studies published in the October 2000 issue of ENT -- Ear, Nose and Throat Journal, and separately in the January 2003 issue of QJM: An International Journal of Medicine, the Zicam Cold Remedy product was shown to reduce the duration of the common cold. The Company also manufactures and markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy Swabs(TM); Zicam Cold Remedy ChewablesTM; Zicam Cold Remedy Oral MistTM; Zicam Cold Remedy RapidMeltsTM; Zicam Allergy Relief; Zicam Extreme Congestion Relief; Zicam Sinus Relief; as well as Zicam Cough products and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at Matrixxinc.com. For investor information, contact Bill Barba, Treasurer, at 602-385-8881.

About GolinHarris
GolinHarris is a leading public relations agency offering a distinctive combination of global resources and personalized service in the Americas, Asia Pacific, Europe and the Middle East. Clients include Dow Chemical Company, McDonald's Corporation, Nintendo of America Inc., Orange, Texas Instruments and Toyota Motor Sales USA, Inc. GolinHarris celebrated its 50th anniversary in 2006, and is proud to have been selected as 2007 Agency of the Year by The Holmes Report, Large PR Agency of the Year in the PRWeek Awards, PRWeek Magazine's 2007 Editors' Choice and 2008 International Agency of the Year
'/>"/>

Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine news :

1. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
2. Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2008 Financial Results
3. Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
5. Matrixx Initiatives, Inc. Reports Fiscal 3rd Quarter Net Sales of $30.8 Million and Net Loss of ($0.07) Per Share
6. Matrixx Initiatives, Inc. Sets Time for Discussion of Third Quarter Fiscal 2008 Financial Results
7. Matrixx Initiatives, Inc. Updates 2007/2008 Cold Season Trends and Fiscal 2008 Sales and Earnings Outlook
8. Matrixx Initiatives, Inc. to Present at the William Blair & Company Small-Cap Growth Stock Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. Health Plans, Employers Take Closer Look at Costs and Expand Disease Management Initiatives in Response to Diabetes Prevalence Increase
11. Newly Reactivated Health Economics Research Institute to Launch New Initiatives for Improving Health Care Delivery